Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14C-radiolabeled cenerimod mass balance study in healthy males
NCT02914223Phase 1Completed
- Sponsor
- Viatris
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cenerimod (2 arms), sponsored by Viatris. Primary endpoint: Cumulative excretion of radioactivity in urine, feces, and expired air up to 99 days. Started Sep 2016; status: completed.
02
Drugs
cenerimod
Beyond the preview
Go deeper on NCT02914223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914223.